Navigation Links
Sorrento Therapeutics, Inc. and QuikByte Software, Inc. Complete Merger
Date:9/18/2009

able exemptions from registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

About Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc., a wholly-owned subsidiary of QuikByte Software, Inc., is a development-stage biopharmaceutical company focused on applying its proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic disease and infectious disease. The Company seeks to construct an antibody library containing fully human antibodies and designed to facilitate the rapid identification and isolation of highly specific, antibody therapeutic product candidates that are fully human and that bind to disease targets appropriate for antibody therapy.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning, including statements regarding expectations, beliefs or intentions regarding our business, technologies and products, financial condition, strategies or prospects, the merger and the other transactions contemplated by the merger agreement. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to, the possibility that some or all of the pending matters and transactions considered by QuikByte may not proceed as contemplated, and by all
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intarcia Therapeutics, Inc. Commences Enrollment of ITCA 650 Phase 2 Study in Type 2 Diabetes
2. Cell Therapeutics, Inc. (CTI) Advances Pixantrone Filing Process in Europe; Submits Pediatric Investigation Plan (PIP)
3. Cell Therapeutics, Inc. (CTI) to Present at BioCenturys NewsMakers in the Biotech Industry Conference
4. Oxygen Biotherapeutics, Inc. Seeks Shareholder Approval for Reverse Stock Split
5. Cell Therapeutics, Inc. (CTI) to Present at Rodman & Renshaw Healthcare Conference
6. Oxygen Biotherapeutics, Inc. to Present at Investment Conferences in New York and Zurich
7. Cell Therapeutics, Inc. Announces Closing of Registered Offering of $30 Million of Preferred Stock and Warrants
8. Cell Therapeutics, Inc. Announces Institutional Investor Purchases $30 Million of Preferred Stock and Warrants
9. Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009
10. Nile Therapeutics, Inc. Announces Dosing of First Patient in Phase 2 Study of CD-NP for the Treatment of Acute Heart Failure
11. Cell Therapeutics, Inc. Announces Exercise of Overallotment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... -- About POCT POCT, also ... laboratory. It helps in making fast clinical decisions, ... POCT is gaining popularity due to the increasing ... diabetes, heart disease, and obesity. It is generally ... minimize errors during the diagnosis of patients. POCT ...
(Date:9/18/2014)... Bryan-College Station, Texas (PRWEB) September 18, 2014 ... University System Chancellor John Sharp, Texas A&M Health ... from the U.S. Department of Health and Human ... GSK today dedicated a national pandemic influenza vaccine ... will serve as an anchor for the Texas ...
(Date:9/18/2014)... 18, 2014 Research and Markets ... Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - ... offering. The global companion diagnostics market ... from 2014 to 2019. Factors such as rising need ... companion diagnostics by the pharmaceutical industry, support from regulatory ...
(Date:9/18/2014)... 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ONTY ... but separate underwritten offerings of 10,000,000 shares of its ... $2.00 per share, for expected gross proceeds of $20 ... Preferred Stock at a price to the public of ... million. Each share of Series A Convertible Preferred Stock ...
Breaking Biology Technology:POCT Market in China 2014-2018 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3
... ... Advisory Board --, SAN DIEGO, July ... it has received regulatory approval to,begin a Phase 2a proof-of-concept clinical ... metabolic arthritis, is a,painful and debilitating disease caused by abnormally elevated ...
... July 9 ATS Medical, Inc.,(Nasdaq: ATSI ... and services, today announced it has obtained new ... of the ATS Open,Pivot(R) Mechanical Heart Valve., ... Open Pivot valve was implanted in Lausanne, Switzerland,on ...
... Genetics,Corporation (CellCyte) (OTC Bulletin Board: CCYG) has engaged ... financial advice and,services. CellCyte seeks to build shareholder ... will work with InCap to initiate a corporate,partnering ... expander and stem cell delivery technologies., "We ...
Cached Biology Technology:Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 2Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 3Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 4ATS Medical Confirms Excellent Durability of the ATS Open Pivot Mechanical Heart Valve 2CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 2CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 3CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 4
(Date:9/18/2014)... PULLMAN, Wash. - Washington State University researchers have developed ... sediment to power waste cleanup in rural areas. ... lead to an inexpensive and quick way to clean ... treatment plants while reducing pollution. , Professor Haluk ... College of Engineering and Architecture discuss the system in ...
(Date:9/18/2014)... a small, icy moon of Uranus, is one of ... solar system. Despite its relatively small size, Miranda appears ... resulted in the formation of at least three remarkable ... , These coronae are visible in Miranda,s southern ... across. Arden corona, the largest, has ridges and troughs ...
(Date:9/18/2014)... team of researchers from McGill University and the ... of polyethylene ,microbeads, Canadian Journal of Fisheries ... originate from cosmetics, household cleansers, or industrial cleansers, ... Owing to their small size and buoyancy, they ... Microplastics are a global contaminant in the world,s ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Microplastic pollution discovered in St. Lawrence River sediments 2
... -- Many shark populations have plummeted in the past three ... fins, as an incidental catch of fisheries targeting other species, ... species. However, until now, a lack of data prevented scientists ... a large geographic scale. In a study published online ...
... Medical Center has been successful in attracting funding of ... funding was awarded in response to an application to ... (hemostaseologist) currently based in the USA, to the Center ... of the application was announced jointly by the Alexander ...
... plant disease normally found in subarctic climates has been identified ... far south as Herefordshire., Sclerotinia subarctica , a fungus ... been found in carrots and meadow buttercups in Perthshire by ... of Life Sciences at the University of Warwick. , It ...
Cached Biology News:Scientists provide first large-scale estimate of reef shark losses in the Pacific Ocean 2Mainz University Medical Center attracts funding of Alexander von Humboldt Professorship 2Mainz University Medical Center attracts funding of Alexander von Humboldt Professorship 3